Medigene AG (MDG1.DE)
EUR 1.08
(-1.64%)
EUR 1.08
(-1.64%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -16.14 Million EUR | -89.21% |
| 2022 | -8.71 Million EUR | 12.72% |
| 2021 | -9.98 Million EUR | 57.21% |
| 2020 | -23.33 Million EUR | -15.73% |
| 2019 | -20.16 Million EUR | -13.11% |
| 2018 | -17.82 Million EUR | -33.13% |
| 2017 | -13.38 Million EUR | -1.31% |
| 2016 | -13.21 Million EUR | -26.6% |
| 2015 | -10.43 Million EUR | -262.34% |
| 2014 | -2.88 Million EUR | 68.06% |
| 2013 | -9.02 Million EUR | 45.13% |
| 2012 | -16.44 Million EUR | -5.02% |
| 2011 | -15.65 Million EUR | 43.27% |
| 2010 | -27.59 Million EUR | -40.51% |
| 2009 | -19.63 Million EUR | -161.95% |
| 2008 | 31.7 Million EUR | 200.1% |
| 2007 | -31.66 Million EUR | -278.84% |
| 2006 | -8.35 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.31 Million EUR | 24.35% |
| 2024 Q2 | -4.09 Million EUR | -23.42% |
| 2023 Q3 | -4.38 Million EUR | -6.61% |
| 2023 FY | -16.48 Million EUR | -89.21% |
| 2023 Q4 | -4.38 Million EUR | 0.0% |
| 2023 Q1 | -3.68 Million EUR | -149.42% |
| 2023 Q2 | -4.11 Million EUR | -11.65% |
| 2022 Q4 | -1.47 Million EUR | 0.0% |
| 2022 Q1 | 7.33 Million EUR | 252.06% |
| 2022 Q2 | -1.73 Million EUR | -123.64% |
| 2022 Q3 | -1.47 Million EUR | 14.71% |
| 2022 FY | -8.71 Million EUR | 12.72% |
| 2021 FY | -9.98 Million EUR | 57.21% |
| 2021 Q3 | -1.39 Million EUR | 40.55% |
| 2021 Q2 | -2.35 Million EUR | 14.69% |
| 2021 Q4 | -4.82 Million EUR | -244.48% |
| 2021 Q1 | -2.75 Million EUR | 81.14% |
| 2020 Q4 | -14.63 Million EUR | -100.0% |
| 2020 FY | -23.33 Million EUR | -15.73% |
| 2020 Q2 | -6.01 Million EUR | 4.32% |
| 2020 Q3 | -7.31 Million EUR | -21.74% |
| 2020 Q1 | -6.28 Million EUR | -2717.29% |
| 2019 Q2 | -8.81 Million EUR | -57.29% |
| 2019 Q4 | 240 Thousand EUR | 104.01% |
| 2019 FY | -20.16 Million EUR | -13.11% |
| 2019 Q1 | -5.6 Million EUR | 6.19% |
| 2019 Q3 | -5.98 Million EUR | 32.17% |
| 2018 FY | -17.82 Million EUR | -33.13% |
| 2018 Q1 | -3.56 Million EUR | -51.45% |
| 2018 Q4 | -5.97 Million EUR | -22.94% |
| 2018 Q3 | -4.86 Million EUR | -41.81% |
| 2018 Q2 | -3.42 Million EUR | 3.79% |
| 2017 Q4 | -2.35 Million EUR | 34.39% |
| 2017 Q3 | -3.58 Million EUR | 14.15% |
| 2017 Q2 | -4.17 Million EUR | -27.43% |
| 2017 Q1 | -3.27 Million EUR | 6.66% |
| 2017 FY | -13.38 Million EUR | -1.31% |
| 2016 Q1 | -1.11 Million EUR | 64.91% |
| 2016 FY | -13.21 Million EUR | -26.6% |
| 2016 Q2 | -3.28 Million EUR | -194.88% |
| 2016 Q4 | -3.51 Million EUR | 33.88% |
| 2016 Q3 | -5.31 Million EUR | -61.79% |
| 2015 FY | -10.43 Million EUR | -262.34% |
| 2015 Q4 | -3.17 Million EUR | -23.18% |
| 2015 Q3 | -2.57 Million EUR | -5.53% |
| 2015 Q2 | -2.44 Million EUR | -8.25% |
| 2015 Q1 | -2.25 Million EUR | -328.6% |
| 2014 Q4 | 986 Thousand EUR | 153.38% |
| 2014 FY | -2.88 Million EUR | 68.06% |
| 2014 Q3 | -1.84 Million EUR | -391.22% |
| 2014 Q2 | -376 Thousand EUR | 77.12% |
| 2014 Q1 | -1.64 Million EUR | 30.14% |
| 2013 Q4 | -2.35 Million EUR | -17.66% |
| 2013 FY | -9.02 Million EUR | 45.13% |
| 2013 Q1 | -2.48 Million EUR | 73.88% |
| 2013 Q2 | -2.18 Million EUR | 12.34% |
| 2013 Q3 | -1.99 Million EUR | 8.34% |
| 2012 Q2 | -2.35 Million EUR | -4.21% |
| 2012 Q4 | -9.52 Million EUR | -313.68% |
| 2012 FY | -16.44 Million EUR | -5.02% |
| 2012 Q3 | -2.3 Million EUR | 2.08% |
| 2012 Q1 | -2.25 Million EUR | 69.54% |
| 2011 Q1 | -3.1 Million EUR | 82.12% |
| 2011 Q2 | -2.42 Million EUR | 21.9% |
| 2011 Q3 | -2.71 Million EUR | -11.92% |
| 2011 Q4 | -7.41 Million EUR | -173.03% |
| 2011 FY | -15.65 Million EUR | 43.27% |
| 2010 Q4 | -17.37 Million EUR | -293.34% |
| 2010 Q2 | -3.16 Million EUR | -19.41% |
| 2010 Q3 | -4.41 Million EUR | -39.39% |
| 2010 Q1 | -2.65 Million EUR | 55.19% |
| 2010 FY | -27.59 Million EUR | -40.51% |
| 2009 Q2 | -5.12 Million EUR | -54.64% |
| 2009 Q4 | -5.92 Million EUR | 9.21% |
| 2009 Q3 | -6.52 Million EUR | -27.18% |
| 2009 FY | -19.63 Million EUR | -161.95% |
| 2009 Q1 | -3.31 Million EUR | 0.0% |
| 2008 FY | 31.7 Million EUR | 200.1% |
| 2007 FY | -31.66 Million EUR | -278.84% |
| 2006 FY | -8.35 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioNTech SE | 690.4 Million EUR | 102.339% |
| CureVac N.V. | -274.2 Million EUR | 94.111% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 111.254% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 111.254% |
| BRAIN Biotech AG | -6.71 Million EUR | -140.491% |
| Formycon AG | -369 Thousand EUR | -4276.423% |
| Heidelberg Pharma AG | -21.2 Million EUR | 23.861% |